Please Wait a Moment
X

Articles

23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

23 Jul, 2020 | Return|

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

CTS Dallas and Phoenix Labs Implements WNV Testing on the Panther

CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...

Read More >

Reminder-MD Revised Headers on CTS forms

Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...

Read More >

Reminder- Check flights and cargo hours for the New Year holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for hol...

Read More >

Reminder-Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

CTS Implements HLA Class I and II Testing on the Gemini

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2020

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >